Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2021

03.11.2020 | Epidemiology

International variation in breast cancer incidence and mortality in young women

verfasst von: Victoria Sopik

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breast cancer in young women (< 40 years) is rare and carries a poor prognosis relative to breast cancer in older women. Most studies examining global breast cancer patterns do not describe the trends in young women specifically.

Methods

Data from GLOBOCAN 2018 were used to compare breast cancer incidence and mortality rates among younger (ages 0–39) vs. older (ages 40+) women across 185 countries. The coefficient of variation (the ratio of the standard deviation to the mean) was used to quantify relative variability.

Results

The risk of developing breast cancer to age 39 ranged from 0.13% in Guinea to 0.95% in South Korea (coefficient of variation: 46%), and the risk of death from breast cancer to age 39 ranged from 0.02% in China to 0.72% in Cameroon (coefficient of variation: 81%). In contrast, the risk of developing breast cancer to age 74 ranged from 1.5% in Mozambique to 12.2% in Belgium (coefficient of variation: 50%), and the risk of death from breast cancer to age 74 ranged from 0.65% in South Korea to 3.0% in Somalia (coefficient of variation: 36%).

Conclusions

Among young women, breast cancer mortality rates varied more worldwide than breast cancer incidence. In contrast, among older women/women of all ages, breast cancer incidence varied more than breast cancer mortality. Further research is required to examine the impact of stage at diagnosis, clinicopathologic features, and treatments received, on variations in the survival and mortality of breast cancer in young women around the world.
Literatur
1.
Zurück zum Zitat Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019. cancer.ca/Canadian-Cancer-Statistics-2019-EN Accessed 25 Nov 2019 Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019. cancer.ca/Canadian-Cancer-Statistics-2019-EN Accessed 25 Nov 2019
2.
Zurück zum Zitat Ferlay J, Ervik M, Lam F, et al (2018). Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer. Accessed 15 Nov 2019 Ferlay J, Ervik M, Lam F, et al (2018). Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer. Accessed 15 Nov 2019
3.
Zurück zum Zitat Narod SA (2012) Breast cancer in young women. Nat Rev Clin Oncol 9:460–70CrossRef Narod SA (2012) Breast cancer in young women. Nat Rev Clin Oncol 9:460–70CrossRef
4.
Zurück zum Zitat Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5:S2-8PubMedPubMedCentral Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5:S2-8PubMedPubMedCentral
5.
Zurück zum Zitat Torre LA, Islami F, Siegel RL, Ward EM, Jemal A (2017) Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 26:444–457CrossRef Torre LA, Islami F, Siegel RL, Ward EM, Jemal A (2017) Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 26:444–457CrossRef
6.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 68(3):94–424 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 68(3):94–424
7.
Zurück zum Zitat Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis. Breast Cancer Res Treat 72:107–115CrossRef Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis. Breast Cancer Res Treat 72:107–115CrossRef
8.
Zurück zum Zitat Carmichael AR, Bates T (2004) Obesity and breast cancer: a review of the literature. Breast 13:85–92CrossRef Carmichael AR, Bates T (2004) Obesity and breast cancer: a review of the literature. Breast 13:85–92CrossRef
9.
Zurück zum Zitat Bellanger M, Zeinomar N, Tehranifar P, Terry MB (2018) are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Glob Oncol. 4:1–16PubMed Bellanger M, Zeinomar N, Tehranifar P, Terry MB (2018) are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Glob Oncol. 4:1–16PubMed
10.
Zurück zum Zitat Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F (2017) Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 18:1579–89CrossRef Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F (2017) Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 18:1579–89CrossRef
11.
Zurück zum Zitat Magrath I, Epelman S (2013) Cancer in adolescents and young adults in countries with limited resources. Curr Oncol Rep 15:332–46CrossRef Magrath I, Epelman S (2013) Cancer in adolescents and young adults in countries with limited resources. Curr Oncol Rep 15:332–46CrossRef
12.
Zurück zum Zitat Trama A, Botta L, Steliarova-Foucher E (2018) Cancer burden in adolescents and young adults: a review of epidemiological evidence. Cancer J 24:256–266CrossRef Trama A, Botta L, Steliarova-Foucher E (2018) Cancer burden in adolescents and young adults: a review of epidemiological evidence. Cancer J 24:256–266CrossRef
13.
Zurück zum Zitat Global Burden of Disease Cancer Collaboration (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–48CrossRef Global Burden of Disease Cancer Collaboration (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–48CrossRef
14.
Zurück zum Zitat Lin L, Yan L, Liu Y, Yuan F, Li H, Ni J (2019) Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol. 12:96CrossRef Lin L, Yan L, Liu Y, Yuan F, Li H, Ni J (2019) Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol. 12:96CrossRef
15.
Zurück zum Zitat Hu K, Ding P, Wu Y, Tian W, Pan T, Zhang S (2019) Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases. BMJ Open 9:e028461CrossRef Hu K, Ding P, Wu Y, Tian W, Pan T, Zhang S (2019) Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases. BMJ Open 9:e028461CrossRef
16.
Zurück zum Zitat Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953CrossRef Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953CrossRef
17.
Zurück zum Zitat NCD Risk Factor Collaboration (NCD-RisC) (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390:2627–2642CrossRef NCD Risk Factor Collaboration (NCD-RisC) (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390:2627–2642CrossRef
18.
Zurück zum Zitat Sengal AT, Haj Mukhtar NS, Vetter M et al (2018) Comparison of receptor-defined breast cancer subtypes between german and sudanese women: a facility-based cohort study. J Glob Oncol 4:1–12PubMed Sengal AT, Haj Mukhtar NS, Vetter M et al (2018) Comparison of receptor-defined breast cancer subtypes between german and sudanese women: a facility-based cohort study. J Glob Oncol 4:1–12PubMed
19.
Zurück zum Zitat McCormack V, Joffe M, van den Berg E et al (2013) Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Cancer Res 15:R84 McCormack V, Joffe M, van den Berg E et al (2013) Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Cancer Res 15:R84
20.
Zurück zum Zitat Newman L, Jenkins B, Chen Y et al (2019) Hereditary susceptibility for triple negative breast cancer associated with western sub-saharan african ancestry: results from an international surgical breast cancer collaborative. Ann Surg 270:484–492CrossRef Newman L, Jenkins B, Chen Y et al (2019) Hereditary susceptibility for triple negative breast cancer associated with western sub-saharan african ancestry: results from an international surgical breast cancer collaborative. Ann Surg 270:484–492CrossRef
21.
Zurück zum Zitat Basro S, Apffelstaedt J (2010) Breast cancer in young women in a limited-resource environment. World J Surg 34:1427–33CrossRef Basro S, Apffelstaedt J (2010) Breast cancer in young women in a limited-resource environment. World J Surg 34:1427–33CrossRef
22.
Zurück zum Zitat Ruddy K, Gelber S, Tamimi R et al (2014) Breast cancer presentation and diagnostic delays in young women. Cancer 120:20–5CrossRef Ruddy K, Gelber S, Tamimi R et al (2014) Breast cancer presentation and diagnostic delays in young women. Cancer 120:20–5CrossRef
23.
Zurück zum Zitat Narod SA, Iqbal J, Miller AB (2015) Why have breast cancer mortality rates declined? J Cancer Policy 5:8–17CrossRef Narod SA, Iqbal J, Miller AB (2015) Why have breast cancer mortality rates declined? J Cancer Policy 5:8–17CrossRef
24.
Zurück zum Zitat Sopik V, Sun P, Narod SA (2017) The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. Breast Cancer Res Treat. 165:391–402CrossRef Sopik V, Sun P, Narod SA (2017) The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. Breast Cancer Res Treat. 165:391–402CrossRef
25.
Zurück zum Zitat Thomas A, Rhoads A, Pinkerton E et al (2019) Incidence and survival among young women with stage I-III breast cancer: SEER 2000–2015. JNCI Cancer Spectr 3:pkz040CrossRef Thomas A, Rhoads A, Pinkerton E et al (2019) Incidence and survival among young women with stage I-III breast cancer: SEER 2000–2015. JNCI Cancer Spectr 3:pkz040CrossRef
26.
Zurück zum Zitat Franzoi MA, Rosa DD, Zaffaroni F et al (2019) Advanced stage at diagnosis and worse clinicopathologic features in young women with breast cancer in brazil: a subanalysis of the AMAZONA III study (GBECAM 0115). J Glob Oncol 5:1–10CrossRef Franzoi MA, Rosa DD, Zaffaroni F et al (2019) Advanced stage at diagnosis and worse clinicopathologic features in young women with breast cancer in brazil: a subanalysis of the AMAZONA III study (GBECAM 0115). J Glob Oncol 5:1–10CrossRef
27.
Zurück zum Zitat Olivier M, Bouaoun L, Villar S et al (2019) Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS One 14:e0210372CrossRef Olivier M, Bouaoun L, Villar S et al (2019) Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS One 14:e0210372CrossRef
28.
Zurück zum Zitat Copson E, Eccles B, Maishman T et al (2013) Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. J Natl Cancer Inst 105:978–88CrossRef Copson E, Eccles B, Maishman T et al (2013) Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. J Natl Cancer Inst 105:978–88CrossRef
29.
Zurück zum Zitat Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G (2019) Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 144:1251–1261CrossRef Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G (2019) Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 144:1251–1261CrossRef
30.
Zurück zum Zitat Martínez MT, Oltra SS, Peña-Chilet M et al (2019) Breast cancer in very young patients in a spanish cohort: age as an independent bad prognostic indicator. Breast Cancer (Auckl) 13:1178223419828766 Martínez MT, Oltra SS, Peña-Chilet M et al (2019) Breast cancer in very young patients in a spanish cohort: age as an independent bad prognostic indicator. Breast Cancer (Auckl) 13:1178223419828766
31.
Zurück zum Zitat Feng F, Wei Y, Zheng K et al (2018) Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. Cancer Med 7:2753–2763CrossRef Feng F, Wei Y, Zheng K et al (2018) Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. Cancer Med 7:2753–2763CrossRef
32.
Zurück zum Zitat Kim JY, Kang D, Nam SJ et al (2019) Clinical features and outcomes of invasive breast cancer: age-specific analysis of a modern hospital-based registry. J Glob Oncol 5:1–9CrossRef Kim JY, Kang D, Nam SJ et al (2019) Clinical features and outcomes of invasive breast cancer: age-specific analysis of a modern hospital-based registry. J Glob Oncol 5:1–9CrossRef
33.
Zurück zum Zitat Vettuparambil A, Rajan G, Chirukandath R, Culas TB (2015) Epidemiology, pathological characteristics and estrogen and progesterone receptor status of operated cases of female breast cancer: a retrospective review of 266 cases from Kerala. Indian J Surg Onco. 6:352–5CrossRef Vettuparambil A, Rajan G, Chirukandath R, Culas TB (2015) Epidemiology, pathological characteristics and estrogen and progesterone receptor status of operated cases of female breast cancer: a retrospective review of 266 cases from Kerala. Indian J Surg Onco. 6:352–5CrossRef
34.
Zurück zum Zitat Kocaöz S, Korukluoğlu B, Parlak Ö, Doğan HT, Erdoğan F (2019) Comparison of clinicopathological features and treatments between pre- and postmenopausal female breast cancer patients - a retrospective study. Prz Menopauzalny 18:68–73PubMedPubMedCentral Kocaöz S, Korukluoğlu B, Parlak Ö, Doğan HT, Erdoğan F (2019) Comparison of clinicopathological features and treatments between pre- and postmenopausal female breast cancer patients - a retrospective study. Prz Menopauzalny 18:68–73PubMedPubMedCentral
35.
Zurück zum Zitat Abahssain H, Lalya I, El M’rabet FZ et al (2010) Breast cancer in moroccan young women: a retrospective study. BMC Res Notes 3:286CrossRef Abahssain H, Lalya I, El M’rabet FZ et al (2010) Breast cancer in moroccan young women: a retrospective study. BMC Res Notes 3:286CrossRef
36.
Zurück zum Zitat Dickens C, Duarte R, Zietsman A et al (2014) Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. Cancer Epidemiol Biomarkers Prev 23:2311–21CrossRef Dickens C, Duarte R, Zietsman A et al (2014) Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. Cancer Epidemiol Biomarkers Prev 23:2311–21CrossRef
37.
Zurück zum Zitat Sayed S, Moloo Z, Wasike R et al (2014) Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Breast 23:591–6CrossRef Sayed S, Moloo Z, Wasike R et al (2014) Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Breast 23:591–6CrossRef
38.
Zurück zum Zitat Effi AB, Aman NA, Koui BS, Koffi KD, Traoré ZC, Kouyate M (2017) Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast. BMC Cancer 17:115CrossRef Effi AB, Aman NA, Koui BS, Koffi KD, Traoré ZC, Kouyate M (2017) Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast. BMC Cancer 17:115CrossRef
Metadaten
Titel
International variation in breast cancer incidence and mortality in young women
verfasst von
Victoria Sopik
Publikationsdatum
03.11.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06003-8

Weitere Artikel der Ausgabe 2/2021

Breast Cancer Research and Treatment 2/2021 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.